Pharma News

STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STRO-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STRO-002 overview

STRO-002 is under development for the treatment of solid tumors, relapsed/refractory cancers like epithelial ovarian cancer, endometrial carcinoma, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer and relapsed/refractory rare pediatric acute myeloid leukemia (AML). It is administered through intravenous route. It is developed based on Xpress CF platform technology. The drug candidate is a potent and Sutro proprietary hemia-sterlin derivative warhead. It is a monoclonal antibody conjugate that acts by targeting folate receptor alpha (FolR alpha).

Sutro Biopharma overview

Sutro Biopharma is a clinical-stage biopharmaceutical company that discovers, develops and manufactures novel cancer medicines which include antibody-drug conjugates (ADC’s), bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways. Sutro Biopharma’s pipeline portfolio includes STRO-001, a CD74 ADC for the treatment of multiple myeloma, lymphomas and STRO-002, targeting ovarian and endometrial cancer. The company develops its pipeline products through the Xpress CF and XpressCF+ platform, a biochemical protein synthesis system that develops therapeutic proteins and discovers drugs for the treatment and prevention of diseases. Sutro Biopharma owns a manufacturing facility in San Carlos, California. The company works in partnership with other pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates. Sutro Biopharma is headquartered in South San Francisco, California, the US.

For a complete picture of STRO-002’s drug-specific PTSR and LoA scores, buy the report here.

Source link
#STRO002 #Sutro #Biopharma #Refractory #Acute #Myeloid #Leukemia #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *